HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

The current work examined the potential of using ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-kind (WT) breast tumor cells and in cells missing purposeful p53 possibly alone or in combination with tamoxifen, while the effectiveness of ABBV-744 was limited to